MYGN
Myriad Genetics Inc
4.00$
+3.1%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -7.0% | +14.9% | +37.3% | -2.8% | +33.0% | -9.2% | -6.9% | -9.2% | -4.4% | -10.4% | -31.2% | |
| – | -12.0% | +10.9% | -4.1% | +8.6% | +6.4% | +11.7% | +24.5% | -43.4% | +14.2% | -5.0% | +11.6% | |
| – | -1.1% | +6.9% | +49.5% | +8.3% | -16.0% | +25.5% | +120.0% | -77.9% | +132.2% | -22.5% | +46.1% | |
| – | -22.3% | +9.8% | -5.2% | +19.8% | -24.2% | +10.1% | +124.8% | -66.1% | +22.6% | -27.3% | +46.1% | |
| – | +3.1% | +8.3% | +0.9% | +7.7% | +34.2% | -35.4% | +2.0% | +11.3% | +12.5% | +6.0% | -4.9% | |
| – | +5.0% | +52.6% | +10.2% | -18.7% | -8.5% | -13.7% | -43.5% | +31.4% | +9.5% | +25.0% | +11.3% | |
| – | +4.7% | +10.2% | +61.9% | +0.8% | +30.9% | -21.1% | -27.3% | +19.9% | +0.2% | -0.4% | -82.0% | |
| – | -6.2% | +18.1% | +116.0% | -7.4% | +50.4% | -15.5% | -30.2% | -6.0% | -8.0% | -24.9% | -41.5% | |
| – | -0.7% | +27.2% | +233.0% | -52.6% | +126.5% | +13.5% | -34.4% | -11.3% | +16.1% | -10.1% | +3.7% | |
| – | -14.8% | +5.2% | +200.8% | -53.0% | +15.3% | +23.9% | +40.0% | -32.8% | +13.6% | +5.3% | -18.5% | |
| – | – | – | – | +4.1% | +15.5% | -82.8% | -4.4% | +8.5% | +14.9% | -21.0% | -46.1% | |
| – | -8.7% | +0.0% | +4.3% | +18.2% | +28.1% | -38.4% | +44.4% | -2.7% | -10.4% | +25.2% | -7.1% | |
| – | – | – | – | – | – | – | – | – | – | +2.9% | +202.8% | |
| – | -7.9% | +13.0% | +2.7% | +25.7% | +12.7% | -19.1% | +9.9% | -8.5% | -11.6% | -10.5% | -47.5% | |
| – | -3,950.0% | – | – | – | -52.7% | -986.7% | – | – | – | – | – | |
| – | -4.7% | -1.5% | -6.3% | +4.7% | +5.6% | -1.6% | +4.3% | +3.3% | +2.7% | +9.4% | +3.0% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.